Supporting breakthroughs in life science & tech
Fåhraeus Startup and Growth
With a dedicated focus on the intersection of life science and tech, we invest €1–6M in Seed to Series A companies across digital health, medtech and life science tools. Drawing on our extensive experience in serial entrepreneurship and business development, we support these innovative ventures to positively impact people and society.
Revolutionising the earlier detection of MRD
SAGA Diagnostics is a precision oncology company focused on ultra-sensitive detection of molecular residual disease. Exited to Roche in May 2026 for up to $595M.
Rapid and precise analysis of biomolecules
Fida Biosystems is a life science tools company developing a microfluidics-based biophysical platform enabling rapid and precise analysis of biomolecules and nanoparticles.
.png)
Proven weight control. For life.
Yazen’s mission is to tackle overweight and obesity head-on. Through their digital platform, a dedicated team of specialists equips individuals with the tools and support needed to achieve and sustain a healthy weight.
First-in-class therapies for thrombo-inflammation
Aplagon is a clinical-stage biopharmaceutical company pioneering first-in-class therapies for thrombo-inflammatory diseases, targeting critical unmet medical needs.
